News & Analysis on Clinical Trial Services & Contract Research And Development
While GSK, AstraZeneca and Eli Lilly have hit the headlines in the UK Serious Fraud Office's (SFO) investigation into illegal bribes paid to Saddam Hussein's Iraqi regime, many more pharma firms are on the organisation's hit list.
One Equity Partners (OEP), the private equity arm of JPMorgan Chase, is in the process of selling its stake in Quintiles for a reported sum of over $3bn.
Applied Biosystems, Pharmos, Pearl Therapeutics, Pacira Pharmaceuticals and Covance have all had people on the move in the world of pharmaceutical manufacturing.
A team of US researchers have uncovered a cocktail of three drugs that could be effective at treating every patient with a particular type of brain cancer that typically has a dismal prognosis.
US-based MPI Research and China's Shanghai Medicilon have formed a joint venture in preclinical services, as they position themselves to cash in on what is a budding market sector in China.
Sanofi-Aventis has decided to pull out of its skin cancer collaboration with IDM Pharma, leaving the Californian biopharma firm considering job cuts as a way to lower costs.
Merck & Co has handed the reins of one of its US active pharmaceutical ingredient (API) manufacturing facilities over to new a owner, who has also secured a lucrative contract manufacturing deal with the drug giant.